EGFR is one of the major driver genes in NSCLC, and approximately 10% of American NSCLC patients and 35% of Eastern Asian NSCLC patients carry tumor-associated mutations in the EGFR gene (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004). Here, EGFR is linked to neoplasm.